SEC Filing Form 4 Summary

Bradley L. Campbell, President and CEO of AMICUS THERAPEUTICS, INC. (FOLD), reported the disposition of 1,008,680 shares of Common Stock on April 27, 2026, at a price of $14.50 per share. This transaction occurred in connection with the acquisition of the Issuer by BioMarin Pharmaceutical Inc. In addition, all stock options held by Mr. Campbell were cancelled and converted into the right to receive a cash payment. These options, totaling 1,720,521 shares with varying exercise prices, were fully vested at the time of the merger. All reported derivative transactions and non-derivative transactions resulted in zero shares held post-transaction.